IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

MORI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.718
NA - Nord America 5.447
EU - Europa 4.977
SA - Sud America 626
AF - Africa 261
OC - Oceania 76
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 18.115
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.201
CN - Cina 2.085
SG - Singapore 1.785
IT - Italia 1.770
GB - Regno Unito 744
HK - Hong Kong 628
IN - India 623
BR - Brasile 481
DE - Germania 423
VN - Vietnam 379
RU - Federazione Russa 376
SE - Svezia 332
JP - Giappone 248
FR - Francia 245
NL - Olanda 208
BD - Bangladesh 183
KR - Corea 174
IE - Irlanda 147
FI - Finlandia 146
CA - Canada 134
ID - Indonesia 120
DK - Danimarca 116
TR - Turchia 83
MX - Messico 77
ZA - Sudafrica 75
AU - Australia 73
PL - Polonia 69
PK - Pakistan 64
IR - Iran 56
CZ - Repubblica Ceca 54
TW - Taiwan 54
ES - Italia 52
CH - Svizzera 45
UA - Ucraina 42
AR - Argentina 41
EG - Egitto 41
CI - Costa d'Avorio 40
BE - Belgio 37
MY - Malesia 37
AT - Austria 35
IQ - Iraq 29
PH - Filippine 29
PE - Perù 25
EC - Ecuador 23
MA - Marocco 23
CL - Cile 22
PT - Portogallo 21
CO - Colombia 20
TH - Thailandia 20
SK - Slovacchia (Repubblica Slovacca) 16
NG - Nigeria 14
RO - Romania 14
AE - Emirati Arabi Uniti 13
GR - Grecia 13
IL - Israele 13
SA - Arabia Saudita 13
TN - Tunisia 12
RS - Serbia 11
BY - Bielorussia 9
KE - Kenya 9
NO - Norvegia 9
NP - Nepal 9
HU - Ungheria 8
AZ - Azerbaigian 7
GH - Ghana 7
JM - Giamaica 7
SC - Seychelles 7
SD - Sudan 7
UZ - Uzbekistan 7
KZ - Kazakistan 6
PY - Paraguay 6
CY - Cipro 5
DZ - Algeria 5
ET - Etiopia 5
GE - Georgia 5
JO - Giordania 5
LU - Lussemburgo 5
LV - Lettonia 5
SN - Senegal 5
BG - Bulgaria 4
HN - Honduras 4
KG - Kirghizistan 4
LT - Lituania 4
MD - Moldavia 4
QA - Qatar 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
YE - Yemen 4
AL - Albania 3
BH - Bahrain 3
BO - Bolivia 3
CR - Costa Rica 3
KH - Cambogia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SV - El Salvador 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
A1 - Anonimo 2
Totale 18.063
Salva come PNG Salva come JPEG
Città #
Singapore 1.028
Milan 663
Ashburn 656
Hong Kong 490
Dallas 465
Southend 445
San Jose 373
Beijing 294
Hefei 267
Chandler 232
Council Bluffs 208
Los Angeles 193
Fairfield 160
Dublin 134
New York 130
Santa Clara 130
Bengaluru 123
Ann Arbor 122
Ho Chi Minh City 114
Frankfurt am Main 109
Wilmington 106
Guangzhou 105
Hanoi 99
Seattle 99
Princeton 93
Lauterbourg 91
Moscow 86
Tokyo 84
Shanghai 83
Helsinki 82
Jakarta 81
Redwood City 76
Seoul 73
Buffalo 71
Phoenix 69
The Dalles 69
Woodbridge 69
Pavia 67
Cambridge 66
Houston 66
Munich 61
Istanbul 53
Rome 52
Dearborn 49
Hangzhou 49
Berlin 47
Columbus 46
São Paulo 44
Boardman 42
Delhi 42
Shenyang 42
Nanjing 41
Abidjan 40
Chicago 40
Des Moines 37
Piscataway 37
Cangzhou 36
San Genesio ed Uniti 36
Changsha 35
London 35
Mumbai 35
Naples 35
Montreal 34
Hyderabad 33
New Delhi 33
Nuremberg 32
Cape Town 31
Taipei 31
Turin 31
Warsaw 31
Wuhan 31
Glasgow 30
San Diego 30
Tianjin 30
Segrate 29
Jinan 27
Amsterdam 26
Dong Ket 26
Medford 26
Turku 26
Kolkata 25
Shenzhen 25
Boston 24
Chennai 24
Lappeenranta 23
Lucknow 23
Rio de Janeiro 23
Genoa 22
Orem 21
Brisbane 20
Florence 20
Brussels 19
Cairo 19
Campinas 19
Grafing 19
Johannesburg 19
Manchester 19
Melbourne 19
Ottawa 19
Toronto 19
Totale 9.863
Salva come PNG Salva come JPEG
Nome #
Biocatalytic synthesis of two pharmacologically active compounds: (S)-pramipexole and its enantiomer, dexpramipexole. 717
An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis 668
Signal Transducer and Activator of Transcription Protein 3 (STAT3) : an Update on its Direct Inhibitors as Promising Anticancer Agents 653
Biocatalysts for the synthesis of pharmacologically active compounds 534
Natural products against key Mycobacterium tuberculosis enzymatic targets : Emerging opportunities for drug discovery 377
Discovery and development of novel salicylate synthase (MbtI) Furanic inhibitors as antitubercular agents 356
(S)-Pramipexole and Its Enantiomer, Dexpramipexole : a New Chemoenzymatic Synthesis and Crystallographic Investigation of Key Enantiomeric Intermediates 317
IRON ACQUISITION AS TARGET FOR NEW ANTITUBERCULAR DRUGS 308
Vecuronium bromide and its advanced intermediates : a crystallographic and spectroscopic study 301
6-Hydroxy-2-methylbenzofuran-4-carboxylic acid 270
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents 262
Synthesis, Characterization, and Biological Evaluation of New Derivatives Targeting MbtI as Antitubercular Agents 256
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus 254
Investigating the inhibition mechanism and catalytic cycle of MbtI, the salicylate synthase from Mycobacterium tuberculosis 249
Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections 246
Natural compounds targeting E. Coli WRBA as antibiofilm agents: Virtual screening, design and synthesis of analogs, biological evaluation 243
Targeting Siderophore-Mediated Iron Uptake in M. abscessus: A New Strategy to Limit the Virulence of Non-Tuberculous Mycobacteria 240
Full spectroscopic characterization of two crystal pseudopolymorphic forms of the antiandrogen cortexolone 17α-propionate for topic application 237
Anti-biofilm efficacy of novel silica-based nanoparticles functionalized withnatural derivatives for surface coating 235
Shedding X-ray light on the role of magnesium in the activity of M. tuberculosis salicylate synthase (MbtI) for drug design 232
Diazabicyclo analogues of maraviroc : synthesis, modeling, NMR studies and antiviral activity 220
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS 218
Benzothiadiazole derivatives endowed with STAT3 inhibition 214
Crystallographic and NMR Investigation of Ergometrine and Methylergometrine, Two Alkaloids from Claviceps purpurea 213
New inhibitors of salicylate synthase (MbtI) from m. tubercolosis: a promising strategy to antitubercular drugs 211
New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI) : Preliminary Biological Evaluation and Molecular Modeling Studies 209
Drugs/lamellae interface influences the inner structure of double-loaded liposomes for inhaled anti-TB therapy: An in-depth small-angle neutron scattering investigation 209
Towards a safe treatment of Insulin Resistance: γ-hydroxy lactone-based derivatives as PPARγ non-agonists 208
Towards the Inhibition of Protein–Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives 204
Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy 200
γ-hidroxy-lactone derivatives as ppar-γ non-agonists blocking cdk5-mediated phosporylation for a safer anti-diabetic treatment 198
Unravelling the Antiproliferative Activity of 1,2,5-oxadiazole Derivatives 196
Ironing out Fe3+ acquisition in M. abscessus: a new strategy to target virulence factors in non-tuberculous mycobacteria 192
Exploring the Inhibition of Iron Acquisition in M. abscessus as a Potential Anti-Virulence Strategy in People with Cystic Fibrosis 190
An Outline of the Latest Crystallographic Studies on Inhibitor-Enzyme Complexes for the Design and Development of New Therapeutics against Tuberculosis 189
Natural and nature-inspired compounds targeting E. coli WrbA as antibiofilm agents: computational studies, synthesis, and biological evaluation 185
Identification of the mechanism of action of 5,6-dimethyl-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide as STAT3 inhibitor 185
Targeting the mycobactin biosynthesis pathway in M. tuberculosis: a step towards the improvement of the anti-virulence activity of MbtI inhibitors 183
Unraveling the interaction mechanism of a benzothiadiazole-2.2-dioxide derivative with STAT3 : towards novel direct inhibitors 183
Synthesis and Characterization of a Tetradentate Bispidine-based Ligand and its Zinc(II) Complex 179
Targeting iron acquisition in M. abscessus: a new strategy for the development of anti-virulence agents for cystic fibrosis patients 178
Unlocking the Antibiofilm Potential of Natural Compounds by Targeting the NADH:quinone Oxidoreductase WrbA 178
Biological Screening and Crystallographic Studies of Hydroxy γ-Lactone Derivatives to Investigate PPARγ Phosphorylation Inhibition 177
Functionalized nanoparticles as potential antibiofilm agents 176
A dual-target approach in anti-tuberculosis therapy: new MptpB/MbtI inhibitors 174
Application of chiral bi- and tetra-dentate bispidine-derived ligands in the copper(II)-catalyzed asymmetric Henry reaction 173
Synthesis and Analytical Characterization of Cyclization Products of 3-Propargyloxy-5-benzyloxy-benzoic Acid Methyl Ester 172
Mechanistic Insights into the Antibiofilm Mode of Action of Ellagic Acid 171
A hit expansion of 3-benzamidopyrazine-2-carboxamide: Toward inhibitors of prolyl-tRNA synthetase with antimycobacterial activity 171
Optimizing the drug discovery process for the development of MbtI inhibitors as promising anti-virulence agents against TB 168
Enhancing the activity of γ-hydroxy lactone derivatives as innovative peroxisome proliferator-activated receptor γ non-agonists inhibiting cyclin-dependent kinase 5-mediated phosphorylation 168
Design, synthesis and biological evaluation of novel antitubercular agents targeting the Salycilate Syntase (MbtI). 168
Exploring the biological activity of a library of 1,2,5-oxadiazole derivatives endowed with antiproliferative activity 167
Discovery of novel SIRT5 activators as potential anti-inflammatory agents 165
Eco-Friendly Bio-Based Solvents for the Acetylation of the Amino Group of Amino Acids 162
Design and synthesis of novel furan-based MbtI inhibitors as potential antitubercular agents 162
Synthesis and crystallographic investigation of two new neutral Ir(III) complexes bearing 6-(phenyl)phenanthridine ligands 161
Development of a novel approach to overcome biofilm formation by natural product derivatives 157
Structural and biochemical investigations into the binding mode of furan-based inhibitors of MbtI from M. tuberculosis 156
Virtual screening and crystallographic studies reveal an unexpected γ-lactone derivative active against MptpB as a potential antitubercular agent 156
Design and synthesis of novel antituberculars targeting the salicylate synthase (MbtI) 155
5,6-Dimethyl-1,3-dihydrobenzo[c][1,2,5]thiadiazole-2,2-dioxide as new STAT3 inhibitor 152
Insights on the Modulation of SIRT5 Activity: A Challenging Balance 145
New strategies to overcome biofilm formation by natural product derivatives 141
γ-HYDROXY LACTONE BASED PPARγ NON-AGONISTS AS SAFE AND INNOVATIVE ANTI-DIABETIC AGENTS. 139
Repurposing of FDA‐Approved Drugs to Disrupt Iron Uptake in Mycobacterium abscessus: Targeting Salicylate Synthase as a Novel Approach 135
Exploring the role of the heterocyclic moiety of 5-(4-nitrophenyl)-2-furoic acid, a promising inhibitor of MBTI from mycobacterium tuberculosis 135
Nature‐Inspired Compounds Targeting Escherichia coli WrbA as Biofilm‐Modulating Agents: Computational Design, Synthesis, and Biological Evaluation 134
Nontuberculous mycobacteria in cystic fibrosis: scouting molecules against M. abscessus iron acquisition pathways 134
An analytical investigation of hydroxylated cinnamoyl polyamines as biomarkers of commercial bee pollen botanical origin 134
Phagocyte-targeting polymersomes as intracellular delivery carriers for enzymatic inhibitors with antitubercular activity 132
Iron Acquisition and Metabolism as a Promising Target for Antimicrobials (Bottlenecks and Opportunities): Where Do We Stand? 131
Polymersomes as selective drug delivery carriers for innovative anti-TB agents 130
Structural insights for the development of novel antituberculars targeting the iron uptake pathway 130
Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors : Design, Synthesis, Inhibition Mechanism and in Vitro Efficacy against Melanoma Cell Lines 128
A click chemistry approach to explore a new scaffold for potential antitubercular agents 127
Methyl 5-(2-Fluoro-4-nitrophenyl)furan-2-carboxylate 125
Multi-target antitubercular drugs: identification of novel dual MbtI and MptpB inhibitors 125
Design and physicochemical characterization of novel hybrid SLN-liposome nanocarriers for the smart co-delivery of two antitubercular drugs 119
5-(4-Nitrophenyl)furan-2-carboxylic Acid 117
Focused Design of Novel Cyclic Peptides Endowed with GABARAP-Inhibiting Activity 116
Synthesis of novel furan-based antitubercolars potentially targeting the methionine aminopeptidases (MtMetAP1a) 115
Synthesis, crystal structure, Hirshfeld surface, computational and antibacterial studies of a 9-phenanthrenecarboxaldehyde-based thiodihydropyrimidine derivative 114
Structural insights into the inhibition of M. tuberculosis salicylate synthase (MbtI) 111
Low-Molecular-Weight Phosphatase B (LMW-MPtpB) inhibition as a strategy to identify new drug candidates against tuberculosis 110
SANS study of lipid-based nanocarriers as inhaled drug delivery systems for anti-tuberculosis chemotherapy 110
Synthesis and characterization of a novel lanthanum (III) complex with a di(2-picolyl)amine-based ligand endowed with fluorescent properties 105
Synthesis and Conformational Analysis of Hydantoin-Based Universal Peptidomimetics 105
Novel quinazolinones active against multidrug‐resistant Mycobacterium tuberculosis: synthesis, antimicrobial evaluation and in silico exploration of PonA1 as a potential target 103
Synthesis and Characterization of New Triazole-Bispidinone Scaffolds and Their Metal Complexes for Catalytic Applications 100
New synergic treatments for inhaled anti-TB therapy: a preliminary SANS study 93
Unravelling the interactions between an antiproliferative 1,2,5-oxadiazole derivative and STAT3 93
Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery 89
Targeting Ubiquitin‐Specific Protease 7 with Novel 5‐Amino‐Pyrazole Inhibitors: Design, Synthesis, and Biological Evaluation 88
Crystal Structure, Hirshfeld Surface Analysis, In-Silico and Antimycotic Investigations of Methyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2-dihydropyrimidine-5-carboxylate 85
Cellulose-Based Nanosponges Loaded with Palladium as Efficient Heterogeneous Catalysts for the Synthesis of Challenging Derivatives with Pharmaceutical Relevance 77
Investigating the Mechanism of Antimycobacterial and Antiproliferative Activity of (E)‐N'‐Benzylidenepyrazine‐2‐Carbohydrazides and their Derivatives 76
Benzyl-N-[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]carbamate 63
null 30
Covalent Inhibitors Targeting Mycobacterial Enzymes: Current Status, Challenges and Future Perspectives 9
Totale 18.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021184 0 0 0 0 0 0 0 0 0 0 73 111
2021/20221.289 79 86 106 69 134 118 84 115 148 78 67 205
2022/20231.648 136 110 124 112 141 210 104 101 238 82 143 147
2023/20242.037 107 111 168 135 289 144 302 161 87 132 196 205
2024/20254.040 185 380 149 309 266 244 206 373 252 425 499 752
2025/20267.309 725 697 921 712 581 448 1.004 354 722 571 574 0
Totale 18.770